PMID- 34012797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Apr
TI  - Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated 
      MAPK/ERK pathway in human lung adenocarcinoma.
PG  - 1841-1856
LID - 10.21037/tlcr-21-299 [doi]
AB  - BACKGROUND: Lung cancer is a malignant tumor with the highest morbidity and 
      mortality rates worldwide, of which lung adenocarcinoma (LUAD) is the most common 
      subtype. Overall, current treatments of LUAD are not satisfactory; therefore, 
      novel targets need to be explored. Let-7b-3p is an important member of the let-7 
      family of microRNAs (miRNAs), and has not been studied separately in LUAD. This 
      study aimed to investigate the role and molecular mechanism of let-7b-3p in LUAD. 
      METHODS: Herein, let-7b-3p expression was detected by quantitative real-time 
      polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH) 
      assays. MTT, colony formation assay, flow cytometry analysis, wound-healing, 
      Transwell and in vivo experiments were conducted to assess let-7b-3p's function 
      in LUAD. The downstream target TFIIB-related factor 2 (BRF2) was predicted using 
      bioinformatics analyses and confirmed by dual-luciferase reporter assay and 
      rescue experiments. Additionally, BRF2 was found to affect the MAPK/ERK pathway 
      through transcriptome sequencing analysis and western blot (WB) assay. RESULTS: 
      Let-7b-3p is downregulated in LUAD cells and tissue samples and low let-7b-3p 
      expression is correlated with a poor prognosis in LUAD patients. Let-7b-3p 
      suppresses the proliferation and metastasis of LUAD cells both in vivo and in 
      vitro by directly targeting the BRF2-mediated MAPK/ERK pathway. CONCLUSIONS: 
      Let-7b-3p inhibits the development of LUAD and is an ideal novel therapeutic 
      target for the treatment of LUAD.
CI  - 2021 Translational Lung Cancer Research. All rights reserved.
FAU - Li, Yongmeng
AU  - Li Y
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Dong, Rui
AU  - Dong R
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Lu, Ming
AU  - Lu M
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Cheng, Chuanle
AU  - Cheng C
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Feng, Zitong
AU  - Feng Z
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Zhao, Renchang
AU  - Zhao R
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Liang, Jinghui
AU  - Liang J
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Han, Jingyi
AU  - Han J
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Jiang, Jin
AU  - Jiang J
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
FAU - Xu-Welliver, Meng
AU  - Xu-Welliver M
AD  - Department of Radiation Oncology, The Ohio State University Wexner Medical 
      Center, Columbus, OH, USA.
FAU - Renaud, Stephane
AU  - Renaud S
AD  - Department of Thoracic Surgery, Institut Lorrain Du Coeur Et Des Vaisseaux Louis 
      Mathieu, Nancy University Hospital, Nancy, France.
FAU - Tian, Hui
AU  - Tian H
AD  - Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC8107730
OTO - NOTNLM
OT  - Lung adenocarcinoma (LUAD)
OT  - MAPK/ERK pathway
OT  - TFIIB-related factor 2 (BRF2)
OT  - let-7b-3p
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tlcr-21-299). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/05/21 06:00
MHDA- 2021/05/21 06:01
PMCR- 2021/04/01
CRDT- 2021/05/20 06:44
PHST- 2021/05/20 06:44 [entrez]
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/05/21 06:01 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - tlcr-10-04-1841 [pii]
AID - 10.21037/tlcr-21-299 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2021 Apr;10(4):1841-1856. doi: 10.21037/tlcr-21-299.